Fig. 5
From: Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancer
Tumor IHC staining and correlation between FAP-positive in cells (IHC) and FAPI-46/dual-tracer uptake (PET/CT)
Patient with distal esophageal cancer, A: HE-staining of primary tumor, B: positive FAP-IHC of the same specimen, C: Maximum intensity projection (MIP) with FAPI-46/dual-tracer PET-positive tumor in projection on the distal esophagus, D: Correlation of CRmax (FAPI-46/dual-tracer PET/CT) and FAP-positive cells (“fpc”, in %) in the IHC